Shijiazhuang Yiling Pharmaceutical Co., Ltd. announces its wholly-owned subsidiary, Wansheng Hengshui Pharmaceutical Co., Ltd., has received approval from the NMPA for its Irbesartan API market launch application. This approval is for domestic production and marks a significant step for the company's API business. The company anticipates this will positively impact its business operations.
Summary generated by AI · Always verify with source document
Securities Code: 002603 Securities Abbreviation: Yiling Pharmaceutical Announcement No.: 2026-033
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Announcement on Receiving Approval for Chemical API Market Launch Application
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.